In the livers of patients with NAFLD, increased poly (ADP-ribose) polymerase 1 (PARP1) activity represses PPARα transactivation and may lead to weakened fatty acid oxidation [157]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.